Navigation Links
Nuvilex, Inc. Announces Business Update Conference Call
Date:7/8/2009

CHERRY HILL, N.J., July 8 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), today announced that it will host an investor conference call on Tuesday, July 14, 2009 at 4:30 PM Eastern Time to discuss current trends in the business and provide an update on the Company's launch of the Last Shot Hangover Remedy.

"In a very difficult economy and market, we are making extraordinary progress towards achieving our stated goals for the current fiscal year," said Martin Schmieg, Chairman and CEO of Nuvilex, Inc. "Based on the recent decline in our stock price, we do not think our current market cap appropriately reflects the remarkable advancements we have been making. As such, we are refining our investor relations program to ensure that our message is being told, heard and understood by both new and existing shareholders. We hope that Tuesday's call will be the start of a change in investor sentiment commensurate with the notable work that is being done to grow the Company's revenues and profits."

To participate in the call, please dial 1-877-407-4018 (U.S.) and 1-201-689-8471 (international). A replay of the call will be available from 7:30 PM ET on July 14, through 11:59 PM ET on July 21. To access the replay, please dial 1-877-660-6853 (U.S.) and 1-201-612-7415 (international). Participants should use account number 3055 and conference ID number 327957 to access the replay.

The call will also be webcast. To access the webcast, please go to: http://viavid.net/dce.aspx?sid=00006703 . A replay of the webcast will also be available at www.nuvilex.com.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy, a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen, which promotes a healthy glucose metabolism; Cinnechol, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink (R), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink (R). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:
    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Amy Glynn/Ashleigh Barreto
    The Ruth Group
    Ph: 646-536-7023/7028
    Email: aglynn@theruthgroup.com
    Email: abarreto@theruthgroup.com

    Press Contact:
    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Announces Monthly Investor Conference Call
2. Nuvilex, Inc. Announces Investor Conference Call and Open House
3. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
4. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
5. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
6. eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
7. Tiger Schulmanns Mixed Martial Arts Announces Winners of 2009 90-Day Challenge
8. Versus Technology, Inc. Announces Sale of Real-Time Location System to the St. Louis VA Medical Center
9. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. The Max Cure Foundation Announces Its First Charity Benefit: The Roar for a Cure Carnival to Be Held on Saturday, August 22, 2009
11. Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... MEDIA, Pa. , June 23, 2016 ... treatments in an outpatient dialysis facility.  Treatments are usually ... to 6 hours per visit, including travel time, equipment ... on a patient, but especially grueling for patients who ... residents of a skilled nursing and rehabilitation centers for ...
(Date:6/23/2016)... 23, 2016 The Biotechnology industry ... to present great opportunities to investors. Stock-Callers.com assesses the ... Corp. (NYSE: XON ), Vertex Pharmaceuticals Inc. ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: